| EXAMINATION | - RING J. ET AL, "Guidelines for treatment of atopic eczema (atopic dermatitis) Part I", JEADV , THE JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, NL, (20120719), vol. 26, no. 9, doi:10.1111/j.1468-3083.2012.04635.x, pages 1045 - 1060, XP093235834 |
| EXAMINATION | - RING J. ET AL, "Guidelines for treatment of atopic eczema (atopic dermatitis) Part II : Guidelines for treatment of atopic eczema", JEADV , THE JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, NL, (20120719), vol. 26, no. 9, doi:10.1111/j.1468-3083.2012.04636.x, ISSN 0926-9959, pages 1176 - 1193, XP055780332 |
| OPPOSITION | - 52a - Ich benötige das genaue Datum, an dem der folgende Beitrag über SlideShare veröffentlicht wurde |
| OPPOSITION | - A Garriga, "71st ANNUAL MEETING OF THE AMERICAN ACADEMY OF DERMATOLOGY (AAD)", Drugs of the Future, (20130301), pages 275 - 279, XP055566346 |
| OPPOSITION | - Anonymous, "ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2015", Regeneron Pharmaceuticals Inc Annual report FORM 10-K, (20160211), pages 1 - 197, XP093238217 |
| OPPOSITION | - Anonymous, "ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2015", SEC, (20160409), pages 1 - 143, SEC, URL: https://web.archive.org/web/20160309040527/https://www.sec.gov/Archives/edgar/data/872589/000153217616000045/regn-123115x10k.htm, XP093238228 |
| OPPOSITION | - Anonymous, "A Study to Assess the Ecacy and Safety of Dupilumab in Participants With Severe Atopic Dermatitis (AD) That Are Not Controlled With Oral Cyclosporine A (CSA) or for Those Who Cannot Take Oral CSA Because it is Not Medically Advisable", Clinical Trials (NCT02755649), (20160824), pages 1 - 20, Clinical Trials (NCT02755649), URL: https://clinicaltrials.gov/study/NCT02755649?tab=history&a=3#version-content-panel, XP093235759 |
| OPPOSITION | - Anonymous, "A Study to Assess the Efficacy and Safety of Dupilumab in Participants With Severe Atopic Dermatitis (AD) That Are Not Controlled With Oral Cyclosporine A (CSA) or for Those Who Cannot Take Oral CSA Because it is Not Medically Advisable", Clinical Trials (NCT02755649), (20200820), pages 1 - 13, XP093238256 |
| OPPOSITION | - Anonymous, "CAS: PubChem: DRUG D10354-Dupilumab", (20140214), (20160112), XP055240675 |
| OPPOSITION | - Anonymous, "DUPIXENT FDA Approval Call", Sanofi, (20170328), pages 1 - 15, Sanofi , URL: /https://www.sanofi.com/assets/dotcom/content-app/events/investor-presentation/2017/Dupixent_FDA_Approval_Investor_call_FINAL.pdf, XP093235857 |
| OPPOSITION | - Anonymous, "HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use DUPIXENT safely and effectively. See full prescribing information for DUPIXENT", FDA, (20170301), pages 1 - 34, XP093238191 |
| OPPOSITION | - Anonymous, " International Nonproprietary Names for Proposed Pharmaceutical Substances (INN).Proposed: List 108", WHO Drug Information, (20120101), vol. 26, no. 4, pages 401 - 472, XP093196048 |
| OPPOSITION | - Anonymous, "IR Thematic call on dupilumab ", Safoni, (20161001), pages 1 - 35, XP093235865 |
| OPPOSITION | - Anonymous, "Open-label Study of Dupilumab in Patients With Atopic Dermatitis", Clinical Trials, (20160612), pages 1 - 15, Clinical Trials, URL: https://clinicaltrials.gov/study/NCT01949311?term=NCT01949311&rank=1&tab=history&a=4#version-content-panel, XP093236917 |
| OPPOSITION | - Anonymous, "REGENERON AND SANOFI ANNOUNCE POSITIVE DUPILUMAB TOPLINE RESULTS FROM TWO PHASE 3 TRIALS IN INADEQUATELY CONTROLLED MODERATE-TO-SEVERE ATOPIC DERMATITIS PATIENTS", Regeneron, pages 1 - 4, Regeneron, URL: https://investor.regeneron.com/news-releases/news-release-details/regeneron-and-sanofi-announce-positive-dupilumab-topline-results, XP093235827 |
| OPPOSITION | - Anonymous, "REGENERON AND SANOFI ANNOUNCE THAT DUPILUMAB USED WITH TOPICAL CORTICOSTEROIDS (TCS) WAS SUPERIOR TO TREATMENT WITH TCS ALONE IN LONG-TERM PHASE 3 TRIAL IN INADEQUATELY CONTROLLED MODERATE-TO-SEVERE ATOPIC DERMATITIS PATIENTS", Regeneron, pages 1 - 4, Regeneron, URL: https://newsroom.regeneron.com/news-releases/news-release-details/regeneron-and-sanofi-announce-dupilumab-used-topical, XP093235832 |
| OPPOSITION | - Anonymous, "Sanofi and Regeneron Announce Positive Study Results for Dupixent ® (dupilumab) in Patients With Moderate-to-Severe Atopic Dermatitis", Sanofi, (20170101), pages 1 - 5, Sanofi, URL: https://www.sanofi.com/en/media-room/press-releases/2017/2017-09-16-06-15-00-1123825, XP093238194 |
| OPPOSITION | - Anonymous, "Sanofi and Regeneron Report Positive Proof- of-Concept Data for Dupilumab, an IL -4R alpha Antibody, in Atopic Dermatitis", Regeneron, (20130302), pages 1 - 4, Regeneron, URL: https://newsroom.regeneron.com/news-releases/news-release-details/sanofi-and-regeneron-report-positive-proof-concept-data, (20190308), XP055566341 |
| OPPOSITION | - Anonymous, "Study of Dupilumab Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis (SOLO 1)", Clinical trials Version 17, (20160816), pages 1 - 8, XP093235820 |
| OPPOSITION | - Anonymous, "Study of Dupilumab (REGN668/SAR231893) Monotherapy Administered to Adult Patients With Moderate-toSevere Atopic Dermatitis (SOLO 2) Version 15 ", Clinical Trials NCT02277769, (20160226), pages 1 - 6, XP093235822 |
| OPPOSITION | - Anonymous, "Study to Assess the Efficacy and Long-term Safety of Dupilumab (REGN668/SAR231893) in Adult Participants With Moderate-to-Severe Atopic Dermatitis (CHRONOS) Version 17", Clinical trials - NCT02260986, (20160902), pages 1 - 7, XP093235829 |
| OPPOSITION | - Anonymous, "Study to Assess the Safety of Dupilumab (REGN668/SAR231893) Administered Concomitantly With Topical Corticosteroids (TCS) in Patients With Moderate-to-severe Atopic Dermatitis (AD)", Clinical Trials NCT01639040 Version 6, (20230927), pages 1 - 4, XP093235817 |
| OPPOSITION | - D09- Supplementary appendix |
| OPPOSITION | - D19a-Supplementary Appendix |
| OPPOSITION | - D19b - Protocol |
| OPPOSITION | - D37- EMA. Annex I Summary of product characteristics for dupilumab |
| OPPOSITION | - D3a-Protocol |
| OPPOSITION | - D3 - Supplementary Appendix |
| OPPOSITION | - D50-Patentee's submission dated 2 December 2020 |
| OPPOSITION | - D51-Patentee's submission dated 24 August 2022 |
| OPPOSITION | - D52b - need to know the exact date on which the following post was published on SlideShare |
| OPPOSITION | - D55- Early Access to Medicines Scheme - Information for Applicants |
| OPPOSITION | - D56a- Official confirmation from ClinicalTrials.gov that D11 was published no later than April 26, 2016 |
| OPPOSITION | - D58 - Dupixent 200 mg solution for injection in pre-filled pen |
| OPPOSITION | - "Ectodermal dysplasia: MedlinePlus Medical Encyclopedia", (20160728), pages 1 - 3, URL: https://web.archive.org/web/20160728044113/https://medlineplus.gov/ency/article/001469.htm, XP093281278 |
| OPPOSITION | - Cohen Yehuda Z., Zhang Xiaojia, Xia Binfeng, Kosloski Matthew P., Kamal Mohamed A., Davis John D., Kanamaluru Vanaja, Xu Christine, "Pharmacokinetics of Subcutaneous Dupilumab Injection With an Autoinjector Device or Prefilled Syringe", Clinical Pharmacology in Drug Development, GB , (20220501), vol. 11, no. 5, doi:10.1002/cpdd.1073, ISSN 2160-763X, pages 675 - 681, XP093235860 |
| OPPOSITION | - Anonymous, "Passage ; Atopic Dermatitis - Eczema", Anonymous, Johannes Ring , Atopic Dermatitis - Eczema, Switzerland, Springer , (20160301), pages 1 - 21, doi:10.1007/978-3-319-22243-1, ISBN 978-3-319-22242-4, XP093235806 |
| OPPOSITION | - Joost, Th.v. ; Kozel, M.M.A. ; Tank, B. ; Troost, R. ; Prens, E.P., "Cyclosporine in atopic dermatitis:Modulation in the expression of immunologic markers in lesional skin", Journal of the American Academy of Dermatology, US , (19921201), vol. 27, no. 6, doi:10.1016/0190-9622(92)70288-Q, ISSN 0190-9622, pages 922 - 928, XP023982703 |
| OPPOSITION | - Thaci Diamant , Eric L Simpson, Lisa A Beck, Thomas Bieber, Andrew Blauvelt, Kim Papp, Weily Soong, Margitta Worm, Jacek Cszepietowski, Howard Sofen, Makoto Kawashima, Richard Wu, Steven P Weinstein, Neil Mh Graham, Gianluca Pirozzi, Ariel Teper, E Rand Sutherland, Vera Mastey, Neil Stahl, George D Yancopoulos, Marius Ardeleanu, "Efficacy and safety of dupilumab in adults with moderate- to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial", The Lancet, (20150101), doi:10.1016/50140-6736(15)00388-8, pages 1 - 13, XP093235802 |
| OPPOSITION | - Werfel Thomas, Kapp Alexander, "Atopic dermatitis and allergic contact dermatitis", Allergy, Elsevier , (20120101), pages 263 - 286, doi:10.1016/C2009-0-46113-0, ISBN 978-0-7234-3658-4, XP093235762 |
| OPPOSITION | - Sidbury Robert, Davis Dawn M, Cohen David E, Cordoro Kelly M, Berger Timothy G, Bergman James N, Chamlin Sarah L, Cooper Kevin D, Feldman Steven R, Hanifin Jon M, Krol Alfons, Margolis David J, Paller Amy S, Schwarzenberger Kathryn, Silverman Robert A, Simpson Eric L, Tom Wynnis L, Williams Hywel C, Elmets Craig A, Block Julie, Harrod Christopher G, Smith Begolka Wendy, Eichenfield Lawrence F, "Guidelines of care for the management of atopic dermatitis Section 3. Management and treatment with phototherapy and systemic agents", Journal of the American Academy of Dermatology, (20140101), vol. 71, no. 2, doi:10.1016/j.jaad.2014.03.030, pages 327 - 349, XP093235813 |
| OPPOSITION | - Simpson Eric L.; Bieber Thomas; Eckert Laurent; Wu Richard; Ardeleanu Marius; Graham Neil M.H.; Pirozzi Gianluca; Mastey Vera, "Patient burden of moderate to severe atopic dermatitis (AD): Insights from a phase 2b clinical trial of dupilumab in adults", Journal of the American Academy of Dermatology, US , (20160114), vol. 74, no. 3, doi:10.1016/j.jaad.2015.10.043, ISSN 0190-9622, pages 491 - 498, XP029419104 |
| OPPOSITION | - Simpson Eric L., Gadkari Abhijit, Worm Margitta, Soong Weily, Blauvelt Andrew, Eckert Laurent, Wu Richard, Ardeleanu Marius, Graham Neil M.H., Pirozzi Gianluca, Sutherland E. Rand, Mastey Vera, "Dupilumab therapy provides clinically meaningful improvement in patient-reported outcomes (PROs): A phase IIb, randomized, placebo-controlled, clinical trial in adult patients with moderate to severe atopic dermatitis (AD)", Journal of the American Academy of Dermatology, US , (20160901), vol. 75, no. 3, doi:10.1016/j.jaad.2016.04.054, ISSN 0190-9622, pages 1 - 10, XP093238127 |
| OPPOSITION | - Eichenfield E, Tom Wynnis L, Chamlin Sarah L, Feldman Steven R, Hanifin Jon M, Simpson Eric L, Berger Timothy G, Bergman James N, Cohen David E, Cooper Kevin D, Cordoro Kelly M, Davis Dawn M, Krol Alfons, Margolis David J, Paller Amy S, Schwarzenberger Kathryn, Silverman Robert A, Williams Hywel C, Elmets Craig A, Block Julie, Harrod Christopher G, Smith Begolka Wendy, Sidbury Robert, "Guidelines of care for the management of atopic dermatitis Section 1. Diagnosis and assessment of atopic dermatitis", Journal of the American Academy of Dermatology, (20130101), vol. 70, no. 2, doi:10.1016/j.jaas.2013.10.010, pages 338 - 351, XP093235809 |
| OPPOSITION | - Eichenfield Lawrence F, Tom Wynnis L, Berger Timothy G, Krol Alfons, Pallet Amy S, Schwarzenberger Kathryn, Bergman James N, Chamlin Sarah L, Cohen David E, Cooper Kevin D, Cordoro Kelly M, Davis Dawn M, Feldman Steven R, Hanifin Jon M, Margolis David J, Silverman Robert A, Simpson Eric L, Williams Hywel C, Elmets Craig A, Block Julie, Harrod Christopher G, Smith Begolka Wendy, Sidbury Robert,, "Guidelines of care for the management of atopic dermatitis Section 2. Management and treatment of atopic dermatitis with topical therapies", Journal of the American Academy of Dermatology, (20140101), vol. 71, no. 1, doi:10.1016/j.jaas.2014.03.023, pages 116 - 132, XP093235811 |
| OPPOSITION | - Khattri Saakshi, Shemer Avner, Rozenblit Mariya, Dhingra Nikhil, Czarnowicki Tali, Finney Robert, Gilleaudeau Patricia, Sullivan-Whalen Mary, Zheng Xiuzhong, Xu Hui, Cardinale Irma, De Guzman Strong Cristina, Gonzalez Juana, Suárez-Fariñas Mayte, Krueger Jim G., Guttman-Yassky Emma, "Cyclosporine in patients with atopic dermatitis modulates activated inflammatory pathways and reverses epidermal pathology", Journal of Allergy and Clinical Immunology, AMSTERDAM, NL , (20140601), vol. 133, no. 6, doi:10.1016/j.jaci.2014.03.003, ISSN 0091-6749, pages 1626 - 1634, XP093238084 |
| OPPOSITION | - Hong Judith, Buddenkotte Joerg, Berger Timothy G., Steinhoff Martin, "Management of Itch in Atopic Dermatitis", Seminars in Cutaneous Medicine and Surgery (Author manuscript), (20110601), vol. 30, no. 2, doi:10.1016/j.sder.2011.05.002, pages 1 - 30, XP093238032 |
| OPPOSITION | - Tsianakas Athanasios; Stander Sonja, "Dupilumab: a milestone in the treatment of atopic dermatitis", The Lancet, AMSTERDAM, NL , (20151008), vol. 387, no. 10013, doi:10.1016/S0140-6736(15)00389-X, ISSN 0140-6736, pages 4 - 5, XP029378550 |
| OPPOSITION | - Blauvelt Andrew; de Bruin-Weller Marjolein; Gooderham Melinda; Cather Jennifer C; Weisman Jamie; Pariser David; Simpson Eric L; Papp Kim A; Hong H Chih-Ho; Rubel Diana; Foley Peter; Prens Errol; Griffiths Christopher E M; Etoh Takafumi; Pinto Pedro Herranz; Pujol Ramon M; Szepietowski Jacek C; Ettler Karel; Kemény Lajos; Zhu Xiaoping; Akinlade Bolanle; Hultsch Thomas; Mastey Vera; Gadkari Abhijit; Eckert Laurent; Amin Nikhil; Graham Neil M H; Pirozzi Gianluca; Stahl Neil; Yancopoulos George D; Shumel Brad, "Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial", The Lancet, AMSTERDAM, NL , (20170504), vol. 389, no. 10086, doi:10.1016/S0140-6736(17)31191-1, ISSN 0140-6736, pages 2287 - 2303, XP085061188 |
| OPPOSITION | - Jm Hanifin, Thurston M, Omoto M, Cherill R, Sj Tofte, Graeber M, "The eczema area and severity index (EASI): assessment of reliability in atopic dermatitis", Experimental Dermatology, (20010101), vol. 10, doi:10.1034/j.1600-0625.2001.100102.x, pages 11 - 18, XP055152651 |
| OPPOSITION | - Lisa A. Beck, Diamant Thai, Jennifer D. Hamilton, Neil M. Graham, Thomas Bieber, Ross Rocklin, Jeffrey E. Ming, Haobo Ren, Richard Kao, Eric Simpson, Marius Ardeleanu, Steven P. Weinstein, Gianluca Pirozzi, Emma Guttman-Yassky, Mayte Suárez-Fariñas, Melissa D. Hager, Neil Stahl, George D. Yancopoulos, Allen R. Radin, "Dupilumab treatment in adults with moderate-to-severe atopic dermatitis", NEW ENGLAND JOURNAL OF MEDICINE, THE, (20140710), vol. 371, no. 2, doi:10.1056/NEJMoa1314768, pages 130 - 138, XP002774987 |
| OPPOSITION | - Simpson Eric L., Bieber Thomas, Guttman-Yassky Emma, Beck Lisa A., Blauvelt Andrew, Cork Michael J., Silverberg Jonathan I., Deleuran Mette, Kataoka Yoko, Lacour Jean-Philippe, Kingo Külli, Worm Margitta, Poulin Yves, Wollenberg Andreas, Soo Yuhwen, Graham Neil M.H., Pirozzi Gianluca, Akinlade Bolanle, Staudinger Heribert, Mastey Vera, Eckert Laurent, Gadkari Abhijit, Stahl Neil, Yancopoulos George D., Ardeleanu Marius, "Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis", The New England journal of medicine, US , (20161001), vol. 375, no. 24, doi:10.1056/NEJMoa1610020, ISSN 0028-4793, pages 2335 - 2348, XP093235815 |
| OPPOSITION | - Robinson A J , M Vu , G A Unglik , G Varigos , L Scardamaglia , "Australasian College of Dermatologists Abstracts Presented at the 49th Annual Scientific Meeting 14-17 May 2016 Perth, Western Australia", Australasian College of Dermatologist, AU , (20160420), vol. 57, no. Suppl S1, doi:10.1111/ajd.12480, ISSN 0004-8380, pages 3 - 85, XP071025260 |
| OPPOSITION | - T. Bieber; B. Straeter, "Off‐label prescriptions for atopic dermatitis in Europe", Allergy , United Kingdom , (20140904), vol. 70, no. 1, doi:10.1111/all.12498, ISSN 0105-4538, pages 6 - 11, XP071462056 |
| OPPOSITION | - De Bruin-Weller M S, Bieber T ,Kawashima M ,Schmitt J , Sun X , Gadkari A , Eckert L , Graham Nm , Pirozzi G , Akinlade B , Ardeleanu M , Hultsch T, "Efficacy and safety of dupilumab in adult patients with atopic dermatitis and a history of inadequate response, intolerance, or contraindication to cyclosporine: subgroup analysis from a 1-year trial ", Allergy , United Kingdom , (20170801), vol. 72, doi:10.1111/all.13250, ISSN 0105-4538, pages 47 - 48, XP093236906 |
| OPPOSITION | - De Bruin-Weller M S, Bieber T ,Kawashima M ,Schmitt J , Sun X , Gadkari A , Eckert L , Graham Nm , Pirozzi G , Akinlade B , Ardeleanu M , Hultsch T, "Efficacy and safety of dupilumab in adult patients with atopic dermatitis and an inadequate response, intolerance, or contraindication to cyclosporine: pooled analysis of two 16-week phase 3 trials", Allergy, United Kingdom , (20170801), vol. 72, doi:10.1111/all.13250, ISSN 0105-4538, pages 46 - 47, XP093236901 |
| OPPOSITION | - Y.A. Leshem; T. Hajar; J.M. Hanifin; E.L. Simpson, "What the Eczema Area and Severity Index score tells us about the severity of atopic dermatitis: an interpretability study", British journal of dermatology, (20150416), vol. 172, no. 5, doi:10.1111/bjd.13662, ISSN 0007-0963, pages 1353 - 1357, XP071134496 |
| OPPOSITION | - Werfel Thomas, Heratizadeh Annice, Aberer Werner, Ahrens Frank, Augustin Matthias, Biedermann Tilo, Diepgen Thomas, Fölster‐holst Regina, Gieler Uwe, Kahle Julia, Kapp Alexander, Nast Alexander, Nemat Katja, Ott Hagen, Przybilla Bernhard, Roecken Martin, Schlaeger Martin, Schmid‐grendelmeier Peter, Schmitt Jochen, Schwennesen Thomas, Staab Doris, Worm Margitta, "S2k guideline on diagnosis and treatment of atopic dermatitis - short version", JDDG. JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, DE , (20160101), vol. 14, no. 1, doi:10.1111/ddg.12871, ISSN 1610-0379, pages 92 - 105, XP093235764 |
| OPPOSITION | - M. E. Schram; Ph. I. Spuls; M. M. G. Leeflang; R. Lindeboom; J. D. Bos; J. Schmitt, "EASI, (objective) SCORAD and POEM for atopic eczema: responsiveness and minimal clinically important difference", Allergy , United Kingdom , (20110927), vol. 67, no. 1, doi:10.1111/j.1398-9995.2011.02719.x, ISSN 0105-4538, pages 99 - 106, XP071461010 |
| OPPOSITION | - Ring J., Alomar A., Bieber T., Deleuran M., Fink‐wagner A., Gelmetti C., Gieler U., Lipozencic J., Luger T., Oranje A.P., Schäfer T., Schwennesen T., Seidenari S., Simon D., Ständer S., Stingl G., Szalai S., Szepietowski J.C., Taïeb A., Werfel T., Wollenberg A., Darsow U., "Guidelines for treatment of atopic eczema (atopic dermatitis) Part I", JEADV , The Journal of the European Academy of Dermatology and Venereology, NL , (20120101), vol. 26, no. 8, doi:10.1111/j.1468-3083.2012.04635.x, ISSN 0926-9959, pages 1045 - 1060, XP093235834 |
| OPPOSITION | - Ring J., Alomar A., Bieber T., Deleuran M., Fink-Wagner A., Gelmetti C., Gieler U., Lipozencic J., Luger T., Oranje A.P., Schäfer T., Schwennesen T., Seidenari S., Simon D., Ständer S., Stingl G., Szalai S., Szepietowski J.C., Taïeb A., Werfel T., Wollenberg A., Darsow U., "Guidelines for treatment of atopic eczema (atopic dermatitis) Part II : Guidelines for treatment of atopic eczema", JEADV , The Journal of the European Academy of Dermatology and Venereology, NL , (20120901), vol. 26, no. 9, doi:10.1111/j.1468-3083.2012.04636.x, ISSN 0926-9959, pages 1176 - 1193, XP055780332 |
| OPPOSITION | - Mcgregor Sean, Farhangian Michael E, Feldman Steven R, "Dupilumab for the treatment of atopic dermatitis: A clinical trial review", EXPERT OPINION ON BIOLOGICAL THERAPY , (20151102), vol. 15, no. 11, doi:10.1517/14712598.2015.1076388, ISSN 1471-2598, pages 1657 - 1660, XP093235840 |
| OPPOSITION | - Tsianakas A, Luger Ta, "The anti-IL-4 receptor alpha antibody dupilumab: facing a new era in treating atopic dermatitis", EXPERT OPINION ON BIOLOGICAL THERAPY, (20151102), vol. 15, no. 11, doi:10.1517/14712598.2015.1095887, ISSN 1471-2598, pages 1661 - 1664, XP093235846 |
| OPPOSITION | - Ong Peck Y, "Editorial update on emerging treatments of atopic dermatitis", Expert opinion on emerging drugs England, UK , (20120601), vol. 17, no. 2, doi:10.1517/14728214.2012.668884, ISSN 1744-7623, pages 129 - 133, XP009171977 |
| OPPOSITION | - Periman Laura M, Mah Francis S, Karpecki Paul M, "A Review of the Mechanism of Action of Cyclosporine A: The Role of Cyclosporine A in Dry Eye Disease and Recent Formulation Developments", Clinical Ophthalmology, (20200101), vol. 14, doi:10.2147/OPTH.S279051, ISSN 1177-5483, pages 4187 - 4200, XP093235870 |
| OPPOSITION | - Bai Shuang; Jorga Karin; Xin Yan; Jin Denise; Zheng Yanan; Damico-Beyer Lisa A; Gupta Manish; Tang Meina; Allison David E; Lu Dan; Zhang Yi; Joshi Amita; Dresser Mark J, "A Guide to Rational Dosing of Monoclonal Antibodies", CLINICAL PHARMACOKINETICS, NZ , (20120101), vol. 51, no. 2, doi:10.2165/11596370-000000000-00000, ISSN 0312-5963, pages 119 - 135, XP009184175 |
